

## **DESCRIPTION OF ADDITIONAL SUPPLEMENTARY FILES DOCUMENT**

### **Title: Supplementary Data 1**

Description: Protocol J1P-MC-KFAC(c): A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients with Psoriasis

### **Title: Supplementary Data 2**

Description: Protocol J1P-MC-KFAD(d): A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients with Atopic Dermatitis

### **Title: Supplementary Data 3**

Description: Statistical Analysis Plan Version 1 J1P-MC-KFAC: A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients with Psoriasis

### **Title: Supplementary Data 4**

Description: Statistical Analysis Plan J1P-MC-KFAD (version 2.0): A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients with Atopic Dermatitis